4P-PHARMA
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424933193/en/
(Graphic: Business Wire)
With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model.
Revital Rattenbach, CEO of 4P-Pharma: "As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases."
This additional shareholders' financial backing is a boost that will allow 4P-Pharma to deploy its drug regeneration model triggered by an unrevealed match between established MOA with unexplored targeting of disease biology, paving the way for developing first-in-class therapies.
This cashflow reserve ensures financial stability and operational agility to engage actively external growth opportunities through M&A and licensing-in and accelerate 4P-Pharma's startup studio model for building a balanced pipeline towards the commercial stage.
Revital Rattenbach concludes: "After a decade of existence, 4P-Pharma is opening a novel turning point of its growth. This successful capital-secure will enable us to push forward our patient-centric vision transforming science into success stories for the best for the patients and the whole medical community."
About 4P-Pharma
Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property. The company is headquartered in Lille and Paris and has over 20 employees.
Site internet : https://4p-pharma.com/fr
LinkedIn: https://fr.linkedin.com/company/4p-pharma
X: https://twitter.com/4P_Pharma/
The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424933193/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Release Fourth Quarter & Full Year 2024 Results on Feb. 18, 2025; IFF to Present at 2025 CAGNY Conference on Feb. 20, 202523.1.2025 22:24:00 CET | Press release
IFF (NYSE:IFF) today announced that it will release its fourth quarter and full year 2024 earnings results following the market close on Tuesday, Feb. 18, 2025. The management team will host a live webcast on Wednesday, Feb. 19, 2025, at 9:00 a.m. ET to discuss results and outlook with the investor community. IFF also announced today that the Company’s management will speak at the Consumer Analyst Group of New York (CAGNY) conference on Thursday, Feb. 20, 2025 at 1:00 PM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enh
AIT Worldwide Logistics executives appointed to new leadership roles23.1.2025 20:04:00 CET | Press release
Chief Development Officer, Ray Fennelly, Chief Information Officer, Ann Nemphos, to guide company towards achieving five-year goals AIT Worldwide Logistics, a global supply chain solutions leader, has named Ray Fennelly to the position of chief development officer (CDO) and Ann Nemphos to chief information officer (CIO). This executive management reorganization improves the alignment of the company’s top leadership with its five-year growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250123094755/en/ In their newly-appointed roles, Chief Development Officer, Ray Fennelly, and Chief Information Officer, Ann Nemphos, are positioned to boost support for AIT’s five-year strategic plan. (Photo: Business Wire) Fennelly, a veteran of both the company and the logistics industry, started with AIT 30 years ago and has held numerous leadership roles in that time, most recently serving as CIO. He has been intimately involve
SES Announces Completion of €100m Open Market Repurchase of its NC625 Securities23.1.2025 18:58:00 CET | Press release
SES S.A. announces it has repurchased in the open market an aggregate amount of €99,978,000 principal amount of its €625,000,000 Deeply Subordinated Fixed Rate Resettable Securities issued on 27 May 2021. In accordance with the terms and conditions of the Securities, the purchased Securities will be cancelled. Following these transactions, the outstanding principal amount of the Securities is €525,022,000. Payment in relation to the Securities will be made in accordance with the usual procedures of Clearstream, Luxembourg and/or Euroclear. The success of these transactions reduces SES's outstanding debt obligation, demonstrating SES’s financial flexibility and its strong cash-generation profile. SES may seek to make further repurchases of its Securities from time to time, subject to market conditions. This announcement does not constitute or form part of an offer to sell or purchase, or a solicitation of an offer to sell or purchase the Securities or any other securities. Follow us on:
InMotion Ventures Invests $2 Million in Cyclic Materials, Extending Series B to $55 Million23.1.2025 15:00:00 CET | Press release
The Series B funding will be used to support the opening of Cyclic Materials’ first commercial facilities in the US and Europe Cyclic Materials, the advanced recycling company building a circular supply chain for Rare Earth Elements and other critical materials, today announced a $2 million investment from InMotion Ventures, the investment arm of Jaguar Land Rover (JLR). This latest backing lifts the company’s Series B round to $55 million, underscoring its critical role in advancing sustainable supply chains for the automotive industry and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250123234060/en/ Cyclic Materials extracts REEs from various end-of-life products, including EVs, consumer electronics, and medical equipment. Pictured are recycled EV and hybrid vehicle motors. (Photo: Business Wire) Rare Earth Elements (REEs) are an essential component in permanent magnets, which are found in everything from data ce
Technology Holdings to Rebrand as TH Global Capital and Expand into Asset Management and Growth Advisory23.1.2025 14:56:00 CET | Press release
Technology Holdings, an award-winning global investment banking firm with operations in 13 countries across 5 continents including the Americas, Europe, and Asia-Pacific, announced that it will be rebranding to TH Global Capital. This rebrand reflects the firm’s continued expansion into additional sectors and products including Asset Management and an expanded Growth Advisory offering to create wealth for its clients. TH Global Capital, is designed to reflect the firm’s comprehensive offering, including Sell Side M&A, its Buy Side M&A practice 'TH Buy and Build', Growth Equity, Debt Financing, Financial Sponsor Coverage & Secondaries, IPO Advisory, Asset Management and Growth Advisory services. This includes the launch of TH Global Asset Management and an expanded growth advisory services offering, aimed at helping companies protect and grow their valuations through focused growth strategy advice. The firm also announced it's now becoming a purpose-driven company, with a singular purpo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom